Grifols announced the launch of its latest albumin portfolio innovation, ALBUTEIN FlexBag? (Albumin [Human] U.S.P.) in 5% and 25% concentrations. Meeting the needs of hospitals and pharmacies across the U.S., the ALBUTEIN FlexBag features a port that is easy-to-use, allowing the minimization of bubble accumulation during infusion, and easy-to-spike, helping nurse and hospital teams avoid needle sticks. The FlexBag also features a flexible container that allows for simple storage and greater convenience, with no requirements for vented infusion sets or filters. ALBUTEIN FlexBag 5% and 25% each come in two sizes. The 5% concentration, approved by the U.S. Food and Drug Administration (FDA) in July 2021, features 250 mL and 500 mL bags. Earlier in the year the FDA approved the 25% concentration, which features 50 mL and 100 mL bags. Sustainability was key for Grifols when developing the environmentally friendly ALBUTEIN FlexBag. Both the ALBUTEIN FlexBag flexible container and protective overwrap are latex-free and do not contain polyvinyl chloride (PVC), diethylhexyl phthalate (DEHP) or other plasticizers. In fact, in a study comparing the manufacturing process of ALBUTEIN FlexBag and ALBUTEIN vials, the FlexBag manufacturing life cycle resulted in a 40% reduction in carbon footprint,1 creating a more sustainable option for hospitals and pharmacies. The launch of ALBUTEIN FlexBag solidifies Grifolscommitment to R+D+i, which has enabled the company to further expand its portfolio of plasma-derived medicines for patients and healthcare professionals. It is now available to U.S. healthcare professionals through a broad distribution network.